WHAT THE FIVE TEAMS FOUND · WHITEPAPER · OCTOBER 2026
In the run-up to launch, the signals usually look fine. Awareness is building, forecasts are holding, and early feedback suggests the market is moving. A positive topline read can also make a launch feel more certain than it is. It shows that the market is moving without always showing what is driving it, where resistance is building, or which decision needs attention next.
That is how blind spots form. Sometimes the team senses something is off and the existing read is not specific enough to explain it. Other times the data points broadly in the right direction, and the real issue stays hidden until plans, spend, or field activity have already moved. The problem is rarely a shortage of data. It is that the data does not match the level of detail, the timing, or the decision the launch now requires.
This white paper follows five real, blinded ZoomRx client partnerships where that moment came into focus. Five teams, five therapy areas, five different points in the launch arc. Every one of them changed something concrete as a result: field-force training, messaging, spend, or the order in which messages were delivered.
Get the White paper
Download the White Paper to learn:
-
Where a competitor is actually winning, rather than where it appears to be winning: One team assumed a rival had taken the market. The chart data showed the rival owned a single patient archetype and had barely touched the segments where the new brand was stronger. Training and messaging were re-cut six weeks before launch.
-
How to pressure-test the story everyone already believes: Advocacy groups, reps, and forum threads all blamed safety fear for a funnel leak, and a quarter’s budget was about to follow that story. The patient data pointed somewhere else entirely, and the leak closed within two waves once the team addressed the real cause.
-
Why a well-tested message can still hold prescribing back: Four message claims all tested well on their own, yet prescribing intent kept softening. The issue turned out to be the order the messages were delivered in, not the messages themselves. Intent recovered within one cycle.
ABOUT ZOOMRX INTEGRATED LAUNCH TRACKING
ZoomRx is trusted by 19 of the top 20 global biopharma companies.
Integrated Launch Tracking brings ATU, patient chart data, competitive promotion tracking, promotional effectiveness, and HCP-patient dialogue into one continuous research programme that runs from pre-launch through post-launch. These are configurable layers on the same platform, fielded against the same panels in the same waves, so they can be read against each other when a single source is not enough.
Every metric is scored against where comparable launches in the same therapy area actually sat at the same point in their arc. A number on its own can flatter or alarm. A number against a benchmark tells you whether you are on track.